Aging Is Not a Disease in the Eyes of Regulators. We Are Working to Change That

The geroscience hypothesis — that aging is a primary mechanism driving multiple chronic diseases, and that aging itself can be intervened upon as a clinical category — is no longer scientifically controversial. The regulatory and reimbursement work to make aging billable, indicated, and reimbursable remains unfinished. The CureForge Aging-as-Disease Sub-Institute, under the federation’s HEOR institute, owns that work. Seven specialized AI systems collaborate across the international classification-of-diseases aging-code agent that tracks classification updates and drafts evidence dossiers for re-introduction, the FDA aging-indication pathway agent following the canonical published precedent, the reimbursement classification agent targeting national-coverage-determination pathways for geroprotective interventions, a federation-wide geroscience-evidence aggregator, an aging-indication trial design agent for indication-trials where aging itself is the indication, an aging-biomarker qualification agent for regulatory-grade biomarkers including methylation clocks, and a public-health-authority liaison agent for major U.S. and international counterparts.

Value proposition:

• Aging-classification regulatory pathway as a tractable engineering program
• Aging-biomarker qualification through Drug Development Tool framework
• Cross-jurisdictional public-health-authority coordination